Among these, EGFR-mutant NSCLC represents the most extensively studied subgroup, offering valuable insights into how ctDNA can be used to track treatment response, detect resistance, and inform prognosis in the context of targeted therapy. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.